Respiratory Inhaler Devices Market, 2012 to 2023
Respiratory Inhaler Devices Market: By Product Type (Metered Dose Inhaler, Nebulizer, Dry Powder Inhaler), By Technology (Manually Operated Inhalers, Digitally Operated Inhalers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Market Outline: Respiratory Inhaler Devices Market
Respiratory inhaler devices are the medical devices that deliver the medication to prevent or control the chronic obstructive pulmonary disease (COPD), asthma, and other respiratory disorders. Various types of respiratory inhaler devices are available in the market such as metered dose inhaler, dry powder inhaler, and nebulizer.
Market Dynamics: Respiratory Inhaler Devices Market
Increase in the prevalence of COPD, asthma, and other respiratory disorder, technological advancements in respiratory inhaler devices, rapid industrialization and rise in smoking population are anticipated to fuel the market. Moreover, ease of administration of drug with respiratory inhaler devices, cost-effective of the products, and growing newborn babies and geriatric population who often exposed to one or the other respiratory disorders are anticipated to boost the respiratory inhaler devices market over the forecast period. However, adverse effects associated with drug inhalation, product recalls, lack of single effective inhalers for all types of disease, and lack of awareness about respiratory inhalers in underdeveloped countries expected to hamper the growth of respiratory inhaler devices market over the forecast timeframe.
Market Scope: Respiratory Inhaler Devices Market
Respiratory inhaler devices market is segmented based on the product type, technology, disease indication, and distribution channel
Based on the product type, the market is segmented into the following:
Metered Dose Inhaler
Nebulizer
Dry Powder Inhaler
Based on the technology, the market is segmented into the following:
Manually Operated Inhalers
Digitally Operated Inhalers
Based on the disease indication, the market is segmented into the following:
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Arterial Hypertension
Others
Based on the distribution channel, the market is segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market Summary: Respiratory Inhaler Devices Market
Escalation in the number of industries led to an abnormal increase in environmental pollution that causes respiratory diseases such as COPD and asthma might propel the respiratory inhaler devices market. According to World Health Organization approximately 3 Mn deaths were observed in 2015 around the globe. Increase in the tobacco consumption majorly in middle and low income countries may causes respiratory disorders and which in turn drive the respiratory inhaler devices market. Moreover, most of the market players are focusing on the development of newer respiratory inhaler devices which are more convenient for drug administration. Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies followed by market players for garnering larger revenue share in respiratory inhaler devices market. For instance, in April 2016, AstraZeneca received FDA approval for Bevepsi Aeresphere (glycopyrrolate and formoterol fumarate) inhalation aerosol used in chronic obstructive pulmonary disease (COPD). In addition, in January 2016, Novartis AG collaborated with Qualcomm, Inc. for the innovation of digital technology for Breezhaler inhaler used in the treatment of COPD.
Regional Analysis: Respiratory Inhaler Devices Market
Geographically, global respiratory inhaler devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America respiratory inhaler devices market is growing due to increase in the prevalence of respiratory disorders such as COPD (according to Centers for Disease Control and Prevention 2014, approximately 15.7 Mn Americans were diagnosed with COPD), high awareness about the respiratory inhalers, and technological advancements in the devices are anticipated to fuel the market. Europe respiratory inhaler devices market driven by increase in the prevalence of respiratory disorders such as COPD and asthma majorly in Sweden, Austria, Switzerland, Belgium, and Portugal, adoption of newer respiratory inhaler devices, and expansion of business by market players in the region. For instance, in November 2015 Sandoz launched AirFluSal Forspiro in UK. Asia Pacific respiratory inhaler devices market has a lucrative growth, which is attributed to increase in geriatric and newborn population, rise in health awareness, and growing pollution due to rapid industrialization in the region. Latin America respiratory inhaler devices market is poised to grow at significant rate owing to product approval in Latin America region. For instance, in August 2014, Sandoz received Mexico’s Health Authority (COFEPRIS) approval for the marketing of Airflusal Forspiro used in COPD. Middle East and Africa respiratory inhaler devices market driven by product launchings by the market players in Africa region. For instance, in January 2017, Cipla launched respiratory inhaler Synchrobreathe in South Africa. Moreover, increase in tobacco consumption and increase in pollution due to increasing the number of industries are anticipated to boost the market in the region.
Competition Assessment: Respiratory Inhaler Devices Market
Some of the players in the global respiratory inhaler devices market include:
Cipla Ltd. (India)
Beximco Pharmaceuticals Ltd. (Bangladesh)
Merck & Co., Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
AstraZeneca plc (U.K.)
Boehringer Ingelheim GmbH (Germany)
Koninklijke Philips N.V. (Netherlands)
Teva Pharmaceutical Industries Ltd. (Israel)
OMRON Healthcare Europe B.V. (Netherlands)
Novartis AG (Switzerland)
PARI Medical Holding GmbH (Germany)
Notable Market Developments: Respiratory Inhaler Devices Market
In January 2017, Teva Pharmaceuticals Industries Ltd. received FDA approval for AirDuo RespiClick and ArmonAir RespiClick, which are used in the treatment of Asthma
Market Outline: Respiratory Inhaler Devices Market
Respiratory inhaler devices are the medical devices that deliver the medication to prevent or control the chronic obstructive pulmonary disease (COPD), asthma, and other respiratory disorders. Various types of respiratory inhaler devices are available in the market such as metered dose inhaler, dry powder inhaler, and nebulizer.
Market Dynamics: Respiratory Inhaler Devices Market
Increase in the prevalence of COPD, asthma, and other respiratory disorder, technological advancements in respiratory inhaler devices, rapid industrialization and rise in smoking population are anticipated to fuel the market. Moreover, ease of administration of drug with respiratory inhaler devices, cost-effective of the products, and growing newborn babies and geriatric population who often exposed to one or the other respiratory disorders are anticipated to boost the respiratory inhaler devices market over the forecast period. However, adverse effects associated with drug inhalation, product recalls, lack of single effective inhalers for all types of disease, and lack of awareness about respiratory inhalers in underdeveloped countries expected to hamper the growth of respiratory inhaler devices market over the forecast timeframe.
Market Scope: Respiratory Inhaler Devices Market
Respiratory inhaler devices market is segmented based on the product type, technology, disease indication, and distribution channel
Based on the product type, the market is segmented into the following:
Metered Dose Inhaler
Nebulizer
Dry Powder Inhaler
Based on the technology, the market is segmented into the following:
Manually Operated Inhalers
Digitally Operated Inhalers
Based on the disease indication, the market is segmented into the following:
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Arterial Hypertension
Others
Based on the distribution channel, the market is segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market Summary: Respiratory Inhaler Devices Market
Escalation in the number of industries led to an abnormal increase in environmental pollution that causes respiratory diseases such as COPD and asthma might propel the respiratory inhaler devices market. According to World Health Organization approximately 3 Mn deaths were observed in 2015 around the globe. Increase in the tobacco consumption majorly in middle and low income countries may causes respiratory disorders and which in turn drive the respiratory inhaler devices market. Moreover, most of the market players are focusing on the development of newer respiratory inhaler devices which are more convenient for drug administration. Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies followed by market players for garnering larger revenue share in respiratory inhaler devices market. For instance, in April 2016, AstraZeneca received FDA approval for Bevepsi Aeresphere (glycopyrrolate and formoterol fumarate) inhalation aerosol used in chronic obstructive pulmonary disease (COPD). In addition, in January 2016, Novartis AG collaborated with Qualcomm, Inc. for the innovation of digital technology for Breezhaler inhaler used in the treatment of COPD.
Regional Analysis: Respiratory Inhaler Devices Market
Geographically, global respiratory inhaler devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America respiratory inhaler devices market is growing due to increase in the prevalence of respiratory disorders such as COPD (according to Centers for Disease Control and Prevention 2014, approximately 15.7 Mn Americans were diagnosed with COPD), high awareness about the respiratory inhalers, and technological advancements in the devices are anticipated to fuel the market. Europe respiratory inhaler devices market driven by increase in the prevalence of respiratory disorders such as COPD and asthma majorly in Sweden, Austria, Switzerland, Belgium, and Portugal, adoption of newer respiratory inhaler devices, and expansion of business by market players in the region. For instance, in November 2015 Sandoz launched AirFluSal Forspiro in UK. Asia Pacific respiratory inhaler devices market has a lucrative growth, which is attributed to increase in geriatric and newborn population, rise in health awareness, and growing pollution due to rapid industrialization in the region. Latin America respiratory inhaler devices market is poised to grow at significant rate owing to product approval in Latin America region. For instance, in August 2014, Sandoz received Mexico’s Health Authority (COFEPRIS) approval for the marketing of Airflusal Forspiro used in COPD. Middle East and Africa respiratory inhaler devices market driven by product launchings by the market players in Africa region. For instance, in January 2017, Cipla launched respiratory inhaler Synchrobreathe in South Africa. Moreover, increase in tobacco consumption and increase in pollution due to increasing the number of industries are anticipated to boost the market in the region.
Competition Assessment: Respiratory Inhaler Devices Market
Some of the players in the global respiratory inhaler devices market include:
Cipla Ltd. (India)
Beximco Pharmaceuticals Ltd. (Bangladesh)
Merck & Co., Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
AstraZeneca plc (U.K.)
Boehringer Ingelheim GmbH (Germany)
Koninklijke Philips N.V. (Netherlands)
Teva Pharmaceutical Industries Ltd. (Israel)
OMRON Healthcare Europe B.V. (Netherlands)
Novartis AG (Switzerland)
PARI Medical Holding GmbH (Germany)
Notable Market Developments: Respiratory Inhaler Devices Market
In January 2017, Teva Pharmaceuticals Industries Ltd. received FDA approval for AirDuo RespiClick and ArmonAir RespiClick, which are used in the treatment of Asthma
1. EXECUTIVE SUMMARY
2. GLOBAL RESPIRATORY INHALER DEVICES MARKET INTRODUCTION
2.1. Global Respiratory Inhaler Devices Market – Taxonomy
2.2. Global Respiratory Inhaler Devices Market –Definitions
2.2.1. Product
2.2.2. Technology
2.2.3. Disease indication
2.2.4. Distribution Channel
3. GLOBAL RESPIRATORY INHALER DEVICES MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Respiratory Inhaler Devices Market Dynamics – Factors Impact Analysis
3.6. Global Respiratory Inhaler Devices Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL RESPIRATORY INHALER DEVICES MARKET, BY PRODUCT, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Metered Dose Inhaler
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Nebulizer
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Dry Powder Inhaler
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. GLOBAL RESPIRATORY INHALER DEVICES MARKET FORECAST, BY TECHNOLOGY, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Manually Operated Inhalers
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Digitally Operated Inhalers
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. GLOBAL RESPIRATORY INHALER DEVICES MARKET FORECAST, BY DISEASE INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Asthma
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Chronic Obstructive Pulmonary Disease (COPD)
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Pulmonary Arterial Hypertension
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. GLOBAL RESPIRATORY INHALER DEVICES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. GLOBAL RESPIRATORY INHALER DEVICES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Region, 2017 – 2023
10. NORTH AMERICA RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Metered Dose Inhaler
10.1.2. Nebulizer
10.1.3. Dry Powder Inhale
10.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Manually Operated Inhalers
10.2.2. Digitally Operated Inhalers
10.3. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Asthma
10.3.2. Chronic Obstructive Pulmonary Disease (COPD)
10.3.3. Pulmonary Arterial Hypertension
10.3.4. Others
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
10.7. North America Respiratory Inhaler Devices Market Dynamics – Trends
11. EUROPE RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Metered Dose Inhaler
11.1.2. Nebulizer
11.1.3. Dry Powder Inhale
11.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Manually Operated Inhalers
11.2.2. Digitally Operated Inhalers
11.3. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Asthma
11.3.2. Chronic Obstructive Pulmonary Disease (COPD)
11.3.3. Pulmonary Arterial Hypertension
11.3.4. Others
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
11.7. Europe Respiratory Inhaler Devices Market Dynamics – Trends
12. ASIA-PACIFIC RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Metered Dose Inhaler
12.1.2. Nebulizer
12.1.3. Dry Powder Inhale
12.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Manually Operated Inhalers
12.2.2. Digitally Operated Inhalers
12.3. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Asthma
12.3.2. Chronic Obstructive Pulmonary Disease (COPD)
12.3.3. Pulmonary Arterial Hypertension
12.3.4. Others
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
12.7. Asia- Pacific Respiratory Inhaler Devices Market Dynamics – Trends
13. LATIN AMERICA RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Metered Dose Inhaler
13.1.2. Nebulizer
13.1.3. Dry Powder Inhale
13.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Manually Operated Inhalers
13.2.2. Digitally Operated Inhalers
13.3. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Asthma
13.3.2. Chronic Obstructive Pulmonary Disease (COPD)
13.3.3. Pulmonary Arterial Hypertension
13.3.4. Others
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
13.7. Latin America Respiratory Inhaler Devices Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Metered Dose Inhaler
14.1.2. Nebulizer
14.1.3. Dry Powder Inhale
14.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Manually Operated Inhalers
14.2.2. Digitally Operated Inhalers
14.3. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Asthma
14.3.2. Chronic Obstructive Pulmonary Disease (COPD)
14.3.3. Pulmonary Arterial Hypertension
14.3.4. Others
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
14.7. MEA Respiratory Inhaler Devices Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Cipla Ltd. (India)
15.2.2. Beximco Pharmaceuticals Ltd. (Bangladesh)
15.2.3. Merck & Co., Inc. (U.S.)
15.2.4. GlaxoSmithKline plc (U.K.)
15.2.5. AstraZeneca plc (U.K.)
15.2.6. Boehringer Ingelheim GmbH (Germany)
15.2.7. Koninklijke Philips N.V. (Netherlands)
15.2.8. Teva Pharmaceutical Industries Ltd. (Israel)
15.2.9. OMRON Healthcare Europe B.V. (Netherlands)
15.2.10. Novartis AG (Switzerland)
15.2.11. PARI Medical Holding GmbH (Germany)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL RESPIRATORY INHALER DEVICES MARKET INTRODUCTION
2.1. Global Respiratory Inhaler Devices Market – Taxonomy
2.2. Global Respiratory Inhaler Devices Market –Definitions
2.2.1. Product
2.2.2. Technology
2.2.3. Disease indication
2.2.4. Distribution Channel
3. GLOBAL RESPIRATORY INHALER DEVICES MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Respiratory Inhaler Devices Market Dynamics – Factors Impact Analysis
3.6. Global Respiratory Inhaler Devices Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL RESPIRATORY INHALER DEVICES MARKET, BY PRODUCT, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Metered Dose Inhaler
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Nebulizer
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Dry Powder Inhaler
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. GLOBAL RESPIRATORY INHALER DEVICES MARKET FORECAST, BY TECHNOLOGY, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Manually Operated Inhalers
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Digitally Operated Inhalers
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. GLOBAL RESPIRATORY INHALER DEVICES MARKET FORECAST, BY DISEASE INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Asthma
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Chronic Obstructive Pulmonary Disease (COPD)
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Pulmonary Arterial Hypertension
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. GLOBAL RESPIRATORY INHALER DEVICES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. GLOBAL RESPIRATORY INHALER DEVICES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Region, 2017 – 2023
10. NORTH AMERICA RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Metered Dose Inhaler
10.1.2. Nebulizer
10.1.3. Dry Powder Inhale
10.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Manually Operated Inhalers
10.2.2. Digitally Operated Inhalers
10.3. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Asthma
10.3.2. Chronic Obstructive Pulmonary Disease (COPD)
10.3.3. Pulmonary Arterial Hypertension
10.3.4. Others
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
10.7. North America Respiratory Inhaler Devices Market Dynamics – Trends
11. EUROPE RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Metered Dose Inhaler
11.1.2. Nebulizer
11.1.3. Dry Powder Inhale
11.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Manually Operated Inhalers
11.2.2. Digitally Operated Inhalers
11.3. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Asthma
11.3.2. Chronic Obstructive Pulmonary Disease (COPD)
11.3.3. Pulmonary Arterial Hypertension
11.3.4. Others
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
11.7. Europe Respiratory Inhaler Devices Market Dynamics – Trends
12. ASIA-PACIFIC RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Metered Dose Inhaler
12.1.2. Nebulizer
12.1.3. Dry Powder Inhale
12.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Manually Operated Inhalers
12.2.2. Digitally Operated Inhalers
12.3. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Asthma
12.3.2. Chronic Obstructive Pulmonary Disease (COPD)
12.3.3. Pulmonary Arterial Hypertension
12.3.4. Others
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
12.7. Asia- Pacific Respiratory Inhaler Devices Market Dynamics – Trends
13. LATIN AMERICA RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Metered Dose Inhaler
13.1.2. Nebulizer
13.1.3. Dry Powder Inhale
13.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Manually Operated Inhalers
13.2.2. Digitally Operated Inhalers
13.3. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Asthma
13.3.2. Chronic Obstructive Pulmonary Disease (COPD)
13.3.3. Pulmonary Arterial Hypertension
13.3.4. Others
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
13.7. Latin America Respiratory Inhaler Devices Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA RESPIRATORY INHALER DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Metered Dose Inhaler
14.1.2. Nebulizer
14.1.3. Dry Powder Inhale
14.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Manually Operated Inhalers
14.2.2. Digitally Operated Inhalers
14.3. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Asthma
14.3.2. Chronic Obstructive Pulmonary Disease (COPD)
14.3.3. Pulmonary Arterial Hypertension
14.3.4. Others
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Respiratory Inhaler Devices Market - Opportunity Analysis Index, By Product, By Technology, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023
14.7. MEA Respiratory Inhaler Devices Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Cipla Ltd. (India)
15.2.2. Beximco Pharmaceuticals Ltd. (Bangladesh)
15.2.3. Merck & Co., Inc. (U.S.)
15.2.4. GlaxoSmithKline plc (U.K.)
15.2.5. AstraZeneca plc (U.K.)
15.2.6. Boehringer Ingelheim GmbH (Germany)
15.2.7. Koninklijke Philips N.V. (Netherlands)
15.2.8. Teva Pharmaceutical Industries Ltd. (Israel)
15.2.9. OMRON Healthcare Europe B.V. (Netherlands)
15.2.10. Novartis AG (Switzerland)
15.2.11. PARI Medical Holding GmbH (Germany)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
